用於治療癌症的涉及針對密蛋白18.2之抗體的聯合治療

• 收藏
• 分享

专利权人:

Ganymed Pharmaceuticals GmbH;TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH;TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITA

发明人:

SAHIN, Ugur,TÜRECI, Özlem,MITNACHT-KRAUS, Rita,JACOBS, Stefan Denis,UTSCH, Magdalena Jadwiga,HEINZ, Cornelia Adriana Maria,STADLER, Christiane Regina,斯特凡．丹尼斯．雅各布斯,UTSCH, Magdalena Jadwiga,瑪格達列娜．雅德維加．烏

申请号：

HK18107123.5

公开号：

HK1247567A

申请日:

2018.05.31

申请国别(地区):

HK

年份:

2018

代理人:

摘要：

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/